Inhibrx is a clinical-stage biotechnology company with a pipeline of biologic therapeutic candidates, developed using its protein engineering expertise and proprietary single domain antibody, or sdAb, platform. Co.'s sdAb platform allows it to pursue validated targets with clinical promise, but where other antibody and biologic based approaches have failed. Co.'s existing pipeline is focused on oncology and orphan diseases. Co. has four programs in ongoing clinical trials. Three of these programs are for the treatment of various cancers, and one for the treatment of Alpha-1 Antitrypsin Deficiency. Co.'s pipelines include: INBRX-10, INBRX-109, INBRX-106, and INBRX-105. We show 14 historical shares outstanding datapoints in our coverage of INBX's shares outstanding history.
Understanding the changing numbers of INBX shares outstanding — and
comprehending the concept of differing number of shares outstanding in general comparing companies like INBX versus peers —
is critical for investors. Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies.
Furthermore, via issuance of new shares over time, or the repurchase of existing shares, the number of shares outstanding can fluctuate over the course of history.
With this page we aim to empower investors researching INBX by allowing them to research INBX shares outstanding history
as well as any other stock in our coverage universe. |
Free INBX Email Alerts:
Video: Shares Outstanding Importance
